Is Cipla overvalued or undervalued?

As of May 9, 2025, Cipla is considered undervalued with an attractive valuation grade, a PE Ratio of 22.99, and favorable comparisons to peers like Sun Pharma and Divi's Lab, despite recent stock performance lagging behind the Sensex, while showing strong growth potential with a 54.92% return over three years.

As of 9 May 2025, Cipla's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 22.99, an EV to EBITDA of 15.93, and a PEG Ratio of 0.97, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Cipla's valuation appears more appealing, especially when contrasted with Sun Pharma's PE Ratio of 35.25 and Divi's Lab's significantly high PE Ratio of 79.33. Additionally, Dr. Reddy's Labs, which is also rated attractive, has a lower PE Ratio of 19.49, further supporting the notion that Cipla is undervalued in its sector. While Cipla's recent stock performance has lagged behind the Sensex on a year-to-date basis, its strong return over three years at 54.92% reinforces its potential for growth.

Who are the top shareholders of the Cipla?

The top shareholders of Cipla include promoters, with Yusuf Khwaja Hameid holding 18.68%, institutional investors with mutual funds at 20.51% and foreign institutional investors at 26.28%, and individual shareholders who collectively own 14.13%. The largest public shareholder is the HDFC Large and Mid Cap Fund, holding 5.13%.

The top shareholders of Cipla include a mix of promoters, institutional investors, and individual shareholders. The majority shareholders are the promoters, with Yusuf Khwaja Hameid being the promoter with the highest holding at 18.68%. <BR><BR>In terms of institutional investments, mutual funds hold 20.51% of the shares through 42 schemes, while foreign institutional investors (FIIs) hold 26.28% through 980 different entities. The highest public shareholder is the HDFC Large and Mid Cap Fund, which holds 5.13%. Additionally, individual investors collectively hold 14.13% of the company's shares.

When is the next results date for Cipla?

No Upcoming Board Meetings

What does Cipla do?

Cipla Limited is a prominent Indian pharmaceutical company that manufactures and markets a variety of branded and generic drugs and Active Pharmaceutical Ingredients (APIs). As of March 2025, it reported net sales of ₹6,730 Cr and a net profit of ₹1,222 Cr, with a market cap of ₹121,226 Cr.

Overview: <BR>Cipla Limited is a leading pharmaceutical company in India, engaged in the manufacturing, developing, and marketing of a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs) within the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Cipla was incorporated in the year 1935. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Net Sales: 6,730 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,222 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 121,226 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 23.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.87% <BR>Debt-Equity: -0.25 <BR>Return on Equity: 16.90% <BR>Price to Book: 3.86 <BR><BR>Contact Details: <BR>Address: Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel Mumbai Maharashtra : 400013 <BR>Tel: 91-22-24826000 <BR>Email: cosecretary@cipla.com <BR>Website: http://www.cipla.com

What is the bonus history of the Cipla?

Cipla's most recent bonus issue occurred on April 24, 2006, when the company announced a 3:2 bonus, granting shareholders three shares for every two held, with a record date of April 25, 2006.

Cipla has a bonus history that includes a notable issuance on April 24, 2006. During this event, the company announced a 3:2 bonus issue, which means that for every two shares held, shareholders received three shares. The record date for this bonus was April 25, 2006. This was the latest bonus action recorded for Cipla. If you have any more questions about the company or its financials, feel free to ask!

Has Cipla declared dividend?

Cipla Ltd. has declared a 650% dividend, with an ex-date of June 27, 2025. The company has shown strong total returns over various periods, including a 134.92% total return over the past 5 years.

Cipla Ltd. has declared a 650% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 650%<BR>- Ex-date: 27 Jun 25<BR><BR>Dividend Yield: 0.87%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Cipla experienced a price return of 1.37%, with no dividend return, resulting in a total return of 1.37%.<BR><BR>Over the past year, the price return was 1.39%, with a dividend return of 0.85%, leading to a total return of 2.24%.<BR><BR>In the 2-year period, Cipla saw a significant price return of 54.06% and a dividend return of 2.13%, culminating in a total return of 56.19%.<BR><BR>For the 3-year period, the price return was 53.43% with a dividend return of 2.89%, resulting in a total return of 56.32%.<BR><BR>In the last 4 years, the company achieved a price return of 58.24% and a dividend return of 3.27%, leading to a total return of 61.51%.<BR><BR>Over the past 5 years, Cipla reported a remarkable price return of 130.04% along with a dividend return of 4.88%, resulting in a total return of 134.92%.<BR><BR>Overall, Cipla has declared a substantial dividend and has shown strong total returns over various periods, indicating a positive performance trend for the company.

Who are the peers of the Cipla?

Cipla's peers include Sun Pharma, Divi's Lab, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesciences, Lupin, Aurobindo Pharma, Abbott India, and Alkem Lab. Divi's Lab has the highest 1-year return at 51.96%, while Aurobindo Pharma has the lowest at -6.51%, with Cipla's return at 0.86%.

Peers: Cipla's peers include Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, Abbott India, and Alkem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Aurobindo Pharma, Abbott India, and Alkem Lab, while Average management risk is found at Lupin. Growth is excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., and Lupin, while below average growth is noted for Divi's Lab., Torrent Pharma, Aurobindo Pharma, and Alkem Lab, and the rest. Excellent capital structure is seen in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs., Mankind Pharma, Zydus Lifesci., and Aurobindo Pharma, while good capital structure is observed at Torrent Pharma and Lupin, and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Aurobindo Pharma has the lowest at -6.51%. Cipla's own 1-year return is 0.86%, which is lower than Divi's Lab. and higher than Aurobindo Pharma. Additionally, the six-month returns for Torrent Pharma, Mankind Pharma, Zydus Lifesci., Aurobindo Pharma, and Alkem Lab are negative.

Who are in the management team of Cipla?

As of March 2023, Cipla's management team includes Y K Hamied (Chairman), M K Hamied (Vice Chairman), Umang Vohra (Managing Director & Global CEO), and several independent directors, bringing diverse expertise to the company.

As of March 2023, the management team of Cipla includes the following individuals:<BR><BR>1. Y K Hamied - Chairman (Non-Executive)<BR>2. M K Hamied - Vice Chairman<BR>3. S Radhakrishnan - Non-Executive & Non-Independent Director<BR>4. Ashok Sinha - Non-Executive & Independent Director<BR>5. Peter Mugyenyi - Non-Executive & Independent Director<BR>6. Adil Zainulbhai - Non-Executive & Independent Director<BR>7. Punita Lal - Non-Executive & Independent Director<BR>8. Samina Hamied - Executive Vice Chairperson<BR>9. Umang Vohra - Managing Director & Global CEO<BR>10. Rajendra Chopra - Company Secretary & Compliance Officer<BR>11. Robert A Stewart - Independent Director<BR>12. P R Ramesh - Independent Director<BR>13. Mandar Purushottam Vaidya - Independent Director<BR><BR>This diverse team brings a wealth of experience and expertise to the company.

How big is Cipla?

As of 24th July, Cipla Ltd. has a market capitalization of 119,313.00 Cr, with recent Net Sales of 27,547.62 Cr and a Net Profit of 5,272.52 Cr. The company reported Shareholder's Funds of 31,193.45 Cr and Total Assets of 36,742.17 Cr.

As of 24th July, Cipla Ltd. has a market capitalization of 119,313.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Cipla reported Net Sales of 27,547.62 Cr and a Net Profit of 5,272.52 Cr.<BR><BR>For the latest annual period, the company reported Shareholder's Funds of 31,193.45 Cr and Total Assets of 36,742.17 Cr.

Are Cipla latest results good or bad?

Cipla's latest results show strong revenue growth of 9.08% sequentially, reaching ₹7,589.44 crores, but profitability concerns arise from a decline in operating margins to 25.44%. Overall, while revenue performance is positive, margin compression and reduced investor interest suggest a cautious outlook.

Cipla's latest results present a mixed picture. On one hand, the company achieved a strong revenue growth of 9.08% sequentially and 7.64% year-on-year, reaching a record high of ₹7,589.44 crores. This indicates robust topline momentum and reflects the company's ability to expand its market presence.<BR><BR>However, there are notable concerns regarding profitability. The operating margin has contracted to 25.44%, down from 26.01% in the previous quarter, indicating rising operational pressures. This margin compression, along with a decline in foreign institutional investor interest, raises questions about the company's near-term profitability and investor confidence.<BR><BR>Net profit did increase by 4.13% quarter-on-quarter, reaching ₹1,351.17 crores, but the overall sentiment is cautious due to the margin erosion. The company is navigating a competitive landscape, and while its diversified product portfolio provides stability, the pressure on margins is something to watch closely.<BR><BR>In summary, while Cipla's revenue growth is commendable, the margin compression and investor sentiment issues suggest that the results are not entirely positive. Investors may want to monitor how the company addresses these challenges in the coming quarters.

How has been the historical performance of Cipla?

Cipla has demonstrated strong financial growth, with net sales increasing from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25, and profit after tax rising from 1,546.98 Cr to 5,291.05 Cr during the same period. Key metrics such as operating profit and earnings per share also showed significant improvement, reflecting robust profitability and operational efficiency.

Answer:<BR>Cipla has shown a consistent growth trajectory in its financial performance over the years, with net sales increasing from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25. The total operating income followed a similar upward trend, reaching 27,547.62 Cr in Mar'25 from 19,159.59 Cr in Mar'21. The operating profit (PBDIT) also saw significant growth, climbing to 7,989.77 Cr in Mar'25 from 3,550.19 Cr in Mar'20. Profit before tax rose to 6,820.81 Cr in Mar'25, up from 2,178.18 Cr in Mar'20, while profit after tax reached 5,291.05 Cr in Mar'25, compared to 1,546.98 Cr in Mar'20. The earnings per share (EPS) improved markedly, standing at 65.29 in Mar'25, up from 19.18 in Mar'20. <BR><BR>On the balance sheet side, total assets increased from 23,422.79 Cr in Mar'20 to 36,742.17 Cr in Mar'25, with total liabilities also rising from 23,422.79 Cr to 36,742.17 Cr during the same period. Shareholder's funds grew from 15,763.00 Cr in Mar'20 to 31,193.45 Cr in Mar'25, indicating a strengthening equity position. The cash flow from operating activities improved to 5,004.00 Cr in Mar'25 from 3,068.00 Cr in Mar'20, while net cash inflow turned positive at 30.00 Cr in Mar'25, contrasting with negative outflows in previous years. Overall, Cipla's financial metrics reflect a robust growth pattern and improved profitability over the analyzed period. <BR><BR>Breakdown:<BR>Cipla's financial performance has demonstrated a strong upward trend across multiple key metrics. Net sales surged from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25, while total operating income mirrored this growth, reaching the same figure in Mar'25. Operating profit (PBDIT) rose significantly from 3,550.19 Cr in Mar'20 to 7,989.77 Cr in Mar'25, showcasing improved operational efficiency. Profit before tax increased from 2,178.18 Cr in Mar'20 to 6,820.81 Cr in Mar'25, and profit after tax followed suit, climbing to 5,291.05 Cr from 1,546.98 Cr in Mar'20. The earnings per share (EPS) also saw a remarkable rise, reaching 65.29 in Mar'25, up from 19.18 in Mar'20. <BR><BR>On the balance sheet, total assets grew from 23,422.79 Cr in Mar'20 to 36,742.17 Cr in Mar'25, with total liabilities increasing in tandem. Shareholder's funds strengthened significantly, rising from 15,763.00 Cr to 31,193.45 Cr over the same period. Cash flow from operating activities improved to 5,004.00 Cr in Mar'25, compared to 3,068.00 Cr in Mar'20, and net cash inflow turned positive at 30.00 Cr in Mar'25, contrasting with negative figures in prior years. This overall performance indicates a solid growth trajectory and enhanced profitability for Cipla.

Should I buy, sell or hold Cipla?

Is Cipla technically bullish or bearish?

As of December 1, 2025, Cipla's technical trend has shifted to sideways, with mixed indicators showing a mildly bearish MACD, bullish weekly RSI, and conflicting signals from moving averages and Bollinger Bands, indicating a lack of clear direction.

As of 1 December 2025, the technical trend for Cipla has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed indicators influencing the outlook. The MACD is mildly bearish on both the weekly and monthly time frames, while the RSI shows bullish momentum on the weekly but no signal on the monthly. Moving averages indicate a mildly bullish trend on the daily, contrasting with the bearish signals from Bollinger Bands and KST on the weekly. Dow Theory reflects a mildly bearish stance on the weekly and no trend on the monthly. Overall, the mixed signals suggest a lack of clear direction, reinforcing the sideways trend.

Which are the latest news on Cipla?

Why is Cipla falling/rising?

As of 04-Dec, Cipla Ltd.'s stock price is rising to 1,521.20, reflecting a trend reversal after previous declines and outperforming its sector. Despite a decrease in investor participation, the stock remains liquid, supported by strong financial fundamentals and an attractive valuation.

As of 04-Dec, Cipla Ltd.'s stock price is rising, currently at 1,521.20, with a change of 13.1 (0.87%) upwards. This increase can be attributed to a trend reversal, as the stock has gained after three consecutive days of decline. Additionally, it has outperformed its sector by 0.58% today, indicating a positive performance relative to its peers.<BR><BR>Despite a slight decrease in investor participation, with delivery volume falling by 24.97% against the 5-day average, the stock remains liquid enough for trading, suggesting that there is still sufficient interest among investors. Furthermore, Cipla's financial health is supported by a low Debt to Equity ratio and a healthy long-term growth rate in operating profit of 19.77% annually. The stock's attractive valuation, with a Price to Book Value of 3.7 and a return on equity (ROE) of 16.5, also contributes to its appeal.<BR><BR>Overall, the combination of a recent price increase, positive performance metrics, and solid financial fundamentals indicates that Cipla's stock is currently on an upward trajectory.